Table 2.
List of immunophenotypic differences between HVs and patients prior to SBRT
| Mean | Mean | P-value | Q-value | |
|---|---|---|---|---|
| HV vs Cohort | HV | Cohort | ||
| CD4+CD45RA+CD62L+CD27+ Naïve (% of CD4+CD45RA+ T cells) | 92.04 | 60.59 | <.0001 | <.0001 |
| LIN−HLA-DR+ dendritic cells (% of MNCs) | 3.15 | 1.73 | .0002 | .0101 |
| LIN−HLA-DR+CD33+CD11c++CD16+ (% of LIN−HLA-DR+) | 42.61 | 15.71 | .0012 | .0446 |
| CD4+CD45RA+ Naïve T cells (% of CD4+) | 41.76 | 27.21 | .0017 | .0455 |
| CD4+CD25+ (% of CD4+ T cells) | 23.49 | 9.88 | .0021 | .0455 |
| LIN−DR+CD11cdim (% of LIN−HLA-DR+) | 3.74 | 7.65 | .0025 | .0455 |
| CD4+PD-1+ (% of CD4+ T cells) | 24.32 | 35.02 | .0041 | .0657 |
| CD15+CD16−CD49d+CCR3+ Eosinophils CD66b FITC MFI | 18.91 | 12.79 | .0048 | .0669 |
| CD142+ Monocytes (% of CD14+) | 2.44 | 9.07 | .0095 | .0998 |
| LIN-DR+CD33+CD11c++CD16− (% of LIN−HLA-DR+) | 35.99 | 55.67 | .0102 | .0998 |
| CD19+CD21− (% of CD19+ B cells) | 9.49 | 18.79 | .0108 | .0998 |
| CD19+CD21+ (% of CD19+ B cells) | 90.51 | 81.21 | .0108 | .0998 |
| HV vs HCC/CCA | HV | HCC/CCA | ||
| CD4+CD45RA+CD62L+CD27+ Naïve (% of CD4+CD45RA+ T cells) | 92.04 | 51.75 | <.0001 | <.0001 |
| CD142+ Monocytes (% of CD14+) | 2.44 | 15.83 | <.0001 | .0051 |
| LIN−DR+CD11cdim (% of LIN−HLA-DR+) | 3.74 | 9.54 | .0003 | .0101 |
| CD19+CD21+ (% of CD19+ B cells) | 90.51 | 74.62 | .0013 | .0283 |
| CD19+CD21− (% of CD19+ B cells) | 9.49 | 25.38 | .0013 | .0283 |
| LIN−HLA-DR+CD33+CD11c++CD16+ (% of LIN−HLA-DR+) | 42.61 | 9.21 | .0017 | .0309 |
| CD14+CD16+ Intermediate Monocytes (cells/µl) | 47.53 | 104.00 | .0034 | .0545 |
| CD4+CD45RA+ Naïve T cells (% of CD4+) | 41.76 | 25.18 | .0041 | .0568 |
| HV vs Liver Metastasis | HV | Liver Mets | ||
| CD4+CD45RA+CD62L+CD27+ Naïve (% of CD4+CD45RA+ T cells) | 92.04 | 69.43 | <.0001 | .0049 |
| CD15+CD16+ Neutrophils (cells/µl) | 2931.00 | 5067.00 | .0012 | .0329 |
| LIN−HLA-DR+ Dendritic cells (% of MNCs) | 3.15 | 1.45 | .0013 | .0329 |
| gamma delta T cells (% of CD3+ T cells) | 1.23 | 3.09 | .0015 | .0329 |
| gamma delta T cells (cells/µl) | 13.27 | 35.07 | .0015 | .0329 |
| CD15+SSChi Granulocytes (cells/µl) | 3127.00 | 5198.00 | .0021 | .0386 |
| CD4+CD8+ T cells (cells/µl) | 12.19 | 59.07 | .0033 | .0515 |
| CD4−CD8− T cells (cells/µl) | 22.64 | 43.23 | .0100 | .0995 |
CCA, cholangiocarcinoma; CD, cluster of differentiation; FITC, fluorescein isothiocyanate; HCC, hepatocellular carcinoma; HVs, health volunteers; LIN, lineage marker; MFI, mean fluorescence intensity; PD-1, programmed cell death 1; SBRT, stereotactic radiation therapy.